



AML3D Limited
Unit 4/136 Mooringe Ave
North Plympton SA 5037
AUSTRALIA

info@aml3d.com
+61 8 8258 2658
www.aml3d.com

MARCH 2026 QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C

AML3D Limited (ASX: AL3) ("**AML3D**" or "**the Company**"), a leader in large scale Wire Additive Manufacturing ("**WAM**") technology and 3D metal printing solutions, is pleased to provide the Quarterly Activities Report and Appendix 4C for the quarter ended 31 March 2026 (**3Q26**).

KEY HIGHLIGHTS DURING THE QUARTER

Customer receipts in 3Q26 were **\$2.2 million**, maintaining the run rate from the 3 previous quarters, to give total year to date **customer receipts of \$6.9 million up 20%** on the prior comparable period (**PCP**). This strong and steady customer receipts run rate is underpinned by the continued success of AML3D's US Scale Up strategy which has delivered an additional **\$12.5 million of orders in 3Q26** for a total of **\$20 million of orders year to date**. When combined with A\$9 million of orders in hand¹ at start of FY2026 AML3D already has a **total of \$29 million of orders** for the current financial year.

The key highlights from the quarter include:

- \$9.9 million, 4 ARCEMY® order from Newport News Shipbuilding, part of the largest US military shipbuilder.²
- \$2.6 million order for 5 high demand, non-safety critical, US Navy submarine components.³
- On-time commissioning of a \$1.7 million ARCEMY at US defence, Aerospace and Energy supplier FasTech.⁴

AML3D's current order book supports our decision to expand our US facilities at Stow, Ohio (**Stow**). Increasing the capacity at Stow will also allow AML3D to meet the significant additive manufacturing demand forecasts outlined in the US Department of the Navy's Letter of Intent⁵ (**LOI**) supplied to AML3D in 1Q26, while continuing to expand into additional US industrial manufacturing sectors.

GROWTH STRATEGY

US scale up

The US Scale Up strategy was initiated in 2023 to address strong demand signals for AML3D's proprietary, ARCEMY® advanced additive manufacturing technology from the US defence sector. The initial US Scale Up orders for ARCEMY® systems, additive component manufacturing (**AM components**) and alloy testing supported the US Navy's Submarine Industrial Base (**SIB**) and focussed on accelerating nuclear submarine manufacturing. AML3D's success supporting the SIB has seen ARCEMY® technology deployed to support the broader US Navy Maritime Industrial Base (**MIB**) supply chain, which includes submarines, surface fleet and munitions.

¹ AML3D Ltd, [2025 Annual Report to shareholders.](#), 18 August 2025

² AML3D Ltd, [\\$9.9M ARCEMY X ORDER FROM US MILITARY SHIPBUILDER](#), 17 March 2026

³ AML3D Ltd, [AML3D RECEIVES AU\\$2.6 MILLION PARTS ORDER FOR US NAVY](#), 26 March 2026

⁴ AML3D Ltd, [ARCEMY X OPERATIONAL AT US DEFENCE SUPPLIER FASTECH](#), 01 April 2026

⁵ AML3D Ltd, [US Navy Issues AML3D with Letter of Intent and Forecast](#), 07 July 2026



In the quarter, AML3D received its biggest US Navy contract to date, being a \$9.9 million order for four ARCEMY® systems from Newport News Shipbuilding (NNS). This order followed an initial \$4.5 million, two ARCEMY® system, order from NNS in 2Q26. NNS is a division of Huntington Ingalls Industries, the largest military shipbuilder in the US, supplying US Navy submarines and aircraft carriers. AML3D is also progressing work on the first portable ARCEMY® system⁶ for use by Austal USA, a prime supplier that operates the US Navy's additive manufacturing Centre of Excellence in Danville, Virginia. The portable ARCEMY® system will be supplied in 4Q26, pre-mounted in a shipping container to allow for easy and rapid redeployment or relocation as needed. The expansion of the NNS fleet of ARCEMY® systems from two to 6 in the space of six months and of the fleet of Austal USA operated systems to four with a portable, containerised system is representative of the expected growth forecast in the US Navy LOI.

During the quarter, AML3D also signed a \$2.6 million order for 5 high demand, non-safety critical, US Navy submarine components⁷ that are no longer supported by their original equipment manufacturers. This follows a similar AM components order in 1Q24⁸ and demonstrates the key role AML3D's additive component manufacturing plays in solving US Navy supply chain issues and supporting the submarine program.

AML3D's success supporting the US Navy is also driving the commercial applications of ARCEMY® technology in additional industrial manufacturing markets. At the end of the quarter, AML3D completed final commissioning of a \$1.7 million large scale ARCEMY® X system to FasTech. FasTech is prime US Navy component supplier but also supplies the Aerospace, Energy and other high-demand sectors. Completion of the FasTech order follows final commissioning of an ARCEMY® system to The Tennessee Valley Authority (TVA) in 1Q26⁹. The TVA is the sixth-largest power supplier and largest public utility in the USA. AML3D's ARCEMY® technology was selected after a competitive tender to be part of the TVA's power generation repair fleet.

The increasing size, value and volume of orders in the US, a total of \$29 million orders in hand on 31 March 2026, is a validation for AML3D's decision to initiate the doubling of capacity at Stow. AML3D had already allocated \$12 million to expand US operations at Stow¹⁰ and, as US demand for ARCEMY® systems and AM components increases, AML3D is also continuing several programs to produce material qualification prints for both defence and non-defence industry players in the US.

US Advocacy program

AML3D is expanding the scope of its US advocacy program to access more of the US Navy supply chain with the appointment of new US Defence advisor Larissa Smith, who stepped down as the Director of Additive Manufacturing for the US Navy in recent weeks. Larissa has begun filtering her extensive network of contacts across the US Navy, and its suppliers, to identify opportunities to embed AML3D's ARCEMY systems and component manufacturing capabilities more broadly and deeply in the US Navy supply chain.

AML3D has already established deep relationships and strong brand awareness with key opinion leaders (KOLs) and decision makers in the US Defence, Government and Manufacturing sectors, with the support of Bondi Partners¹¹. This initial phase of the US advocacy program played a critical role in the adoption of AML3D's technology to support the US NAVY Submarine program and its expansion to support the MIB, that includes the US Navy's surface fleet and munitions, alongside submarines. The appointment of our new US Defence advisor will build awareness, at an operational level, across the US Navy supply chain to accelerate adoption of AML3D's ARCEMY® technology. The new phase of our US advocacy program will build on the insights and intelligence gained, to date, from the US MIB leadership to access more of the US Navy supply chain, to deepen existing relationships with Prime suppliers such as HII and Austal USA and optimize AML3D's US expansion plans to meet significant and accelerating demand from the US Defence sector.

⁶ AML3D Ltd, [AML3D Receives \\$1.2M Portable Arcemy System Order](#), 21 July 2025

⁷ AML3D Ltd, [AML3D RECEIVES AUS2.6 MILLION ORDER FOR US NAVY SUBMARINE PARTS](#), 26 March 2026

⁸ AML3D Ltd, [AML3D RECEIVES \\$2M ORDER FROM US NAVY FOR SUBMARINE PARTS](#), 16 August 2023

⁹ AML3D Ltd, [Arcemy X Operational at the Largest Public Utility in USA](#), 04 August 2025

¹⁰ AML3D Ltd, [AML3D TO MORE THAN DOUBLE US MANUFACTURING CAPACITY FOLLOWING A SUCCESSFUL A\\$30M CAPITAL RAISE](#), 22 November 2024

¹¹ AML3D Ltd, [Investor Presentation](#), 15 September 2025



UK & Europe

AML3D has identified the same demand signals in the UK and key European defence markets that supported the launch of the successful US Scale Up strategy. An initial \$1.2 million material feasibility and test block program with BAE Systems UK¹² is progressing as are early stage ARCEMY® system sales negotiations in the UK. In addition, AML3D carried out confidential component manufacturing for a UK defence prime supplier. This initial progress in accessing the UK defence market will likely support the opening of AML3D's \$5 million European Technology Centre in the UK¹³.

Entry into the UK and European defence markets is key to the next phase of AML3D's growth strategy. AML3D is leveraging its successful US Scale Up playbook to accelerate access to European defence markets. In 1Q26 a two-year distribution agreement covering the UK and Europe was put in place with Arc Additive Limited¹⁴ and a similar, Europe only, deal was signed with, German based, DMFG Solutions GmbH¹⁵.

AML3D's entry into the UK defence market, alongside an established track record supporting the US MIB, means the company is extremely well positioned to provide advanced manufacturing in support of the AUKUS defence pact. Key to the success of AUKUS is an acceleration of manufacturing of existing US Navy submarines and the design and build in the UK of a fleet of new nuclear submarines, which will be supplied to the Australian Navy. AML3D's advanced manufacturing technology has repeatedly demonstrated it can be used to significantly accelerate nuclear submarine procurement timelines.

Australia

The final commissioning of \$1 million ARCEMY® enterprise system for the Curtin University (**Curtin**) in Perth, Western Australia was completed in the quarter under review.¹⁶ The Curtin enterprise ARCEMY® system order was placed in 1Q24 with final commissioning timed to align with the expansion of Curtin's additive manufacturing facility to accommodate the system. The Curtin enterprise system will complement the university's existing ARCEMY® small R&D system.

The Curtin enterprise ARCEMY® system will also act as a satellite manufacturing facility for AML3D to demonstrate its advanced additive manufacturing technology to potential customers in the Mining, Agriculture, Oil & Gas sectors alongside the Defence maritime industries. The final commissioning of the Curtin enterprise ARCEMY® system is timely as it aligns with Australian Government's \$12 billion investment to develop an AUKUS Defence Precinct south of Perth.

AML3D's existing relationships with US and UK AUKUS defence suppliers is expected to create additional Australian ARCEMY® system and AM component sales opportunities. AML3D is recognised by Austrade as one of the largest exporters under AUKUS¹⁷ and the Australian Minister for Defence Industry, Pat Conroy, has expressed interest in AML3D's operating model for the US MIB, with a view to incorporating US best practice when integrating additive manufacturing into Australia's AUKUS supply model.

In addition to completing local contracts, AML3D's Australian facilities are providing additional capacity to support US and UK contracts. AML3D's Adelaide facility is currently managing the material feasibility and test block program for BAE Systems UK. Adelaide is also AML3D's Research and Development base and is continuing development of the \$2.24 million ARCEMY® Increase Deposition Rates (**AIDR**) project to accelerate ARCEMY® component production¹⁸. Maintaining AML3D's leadership position in large scale, metal additive manufacturing will be vital to secure ARCEMY®

¹² AML3D Ltd, [AML3D expands into UK Defence market with alloy test contract](#), 15 April 2025

¹³ AML3D Ltd, [AML3D TO MORE THAN DOUBLE US MANUFACTURING CAPACITY FOLLOWING A SUCCESSFUL A\\$30M CAPITAL RAISE](#), 22 November 2024

¹⁴ AML3D Ltd, [AML3D Accelerates Entry into Europe with UK Distributor Deal](#), 28 July 2025

¹⁵ AML3D Ltd, [AML3D Extends European Distribution Capabilities](#), 6 August 2025

¹⁶ AML3D Ltd, [AML3D Advances Growth Strategy with Arcemy Sale](#), 12 June 2023

¹⁷ AML3D Ltd, [AML3D Supports AUKUS Supply Chain](#), 6 January 2025

¹⁸ AML3D Ltd, [AML3D Wins SA Government Grant \\$2.24M Technology Investment](#), 04 June 2024

AML3D Limited ACN 602 857 983 / Australian Patent 2019251514. AML3D®, WAM®, WAMSoft®, ARCEMY® are all registered trademarks for AML3D®.



system sales and contract manufacturing orders over the medium to longer term. During the quarter, AML3D invested a further \$0.27 million in the ADIR project.

FINANCIAL UPDATE

AML3D had cash receipts of \$2.2 million in the March 2026 quarter, which is consistent with the two prior quarters, reflecting AML3D's strong order book at \$29 million of orders in hand on 31 March 2026.

AML3D invested \$0.8 million as a first tranche of the planned, and fully funded, \$12 million investment to double the capacity of the AML3D's US operations. In addition, the \$0.27 million investment in the ADR R&D project during the quarter brings the cumulative investment in the program during FY26 to \$1 million, out of a total project budget of \$2.24 million.

AML3D's strong order book resulted in product manufacturing and operating costs rising to \$2.4 million compared to \$0.1 million in the PCP period.

The company's cash position remains extremely strong at \$26.5 million, on 31 March 2026, providing ample headroom to continue the planned \$12 million expansion of AML3D's US operations and Stow facility and \$5 million investment to establish a European Technology Centre.

OUTLOOK

AML3D had total orders in hand of \$29 million at 31 March 2026. The Company is focussed on expanding our US operations to ensure the successful delivery of these existing orders, while creating additional capacity to accommodate expectations of continued and growing US AM component and ARCEMY® system orders.

The Company has transitioned to a new phase of US Advocacy to leverage our existing strong brand awareness amongst KOLs in the US Defence and industrial manufacturing industries and accelerate greater penetration of the US additive manufacturing markets. This next phase of advocacy is expected to be a key driver of new US Defence orders.

We are also seeing positive early-stage demand for our ARCEMY® technology in Europe, with advanced negotiations underway for the deployment of an ARCEMY® system into the UK defence sector. The commissioning of a UK ARCEMY® system will be the trigger for AML3D's \$5 million investment in a European Technology centre, most likely in the UK. The demand signals within the European defence sector are at the same level that supported entry into the US market and AML3D plans to leverage its US Scale Up playbook to rapidly build an ARCEMY® system, AM component and alloy testing sales pipeline across key European defence markets.

Our Australian operations continue to deliver existing contracts, while providing the additional capacity needed to meet contract obligations while expanding rapidly in the US and entering the European market. AML3D is already recognised as one of Australia's largest exporters under AUKUS. AML3D's expanded manufacturing footprint in the AUKUS hub of Perth, West Australia and existing facilities at the AUKUS hub of Adelaide, South Australia mean AML3D is perfectly positioned to support the emerging Australian AUKUS manufacturing and sustainment program.

The combination of the strong and growing US order book, initial orders in the UK and positioning to support the AUKUS program in Australia give AML3D confidence it will deliver increased orders and profitability over the short, medium and longer term.

This announcement has been authorised for release by the Board of AML3D.



For further information, please contact:

Sean Ebert

Chief Executive Officer

AML3D Limited

T: +61 429 550 593

E: investor@aml3d.com

Hamish McEwin

Chief Financial Officer

AML3D Limited

T: +61 429 550 593

E: investor@aml3d.com

About AML3D Limited

AML3D Limited, a publicly listed technology company founded in 2014, is disrupting metal part supply chains using the Company's patented Wire Additive Manufacturing (WAM[®]) process. WAM[®] combines state-of-the-art welding science, robotics automation, materials engineering and proprietary software to lead metal additive manufacturing globally. AML3D is the OEM of the ARCEMY[®] industrial metal 3D printing systems. ARCEMY[®] uses WAM[®] to provide advanced, automated, on-demand, point-of-need 3D manufacturing solutions that are more efficient, cost-effective and have better ESG outcomes compared to traditional casting, forging and billet machining processes. ARCEMY[®] is IIoT and Industry 4.0 enabled to allow manufacturers across Aerospace, Defence, Maritime, Manufacturing, Mining and Oil & Gas to become globally competitive. AML3D also provides metal 3D printing design engineering services, software licencing, technical support, consumable sales and contract manufacturing services.

For personal use only

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

AML3D Limited

ABN

55 602 857 983

Quarter ended ("current quarter")

31 March 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	2,182	6,922
1.2 Payments for		
(a) research and development	(273)	(1,016)
(b) product manufacturing and operating costs	(2,363)	(3,703)
(c) advertising and marketing	(104)	(253)
(d) leased assets	-	-
(e) staff costs	(1,197)	(4,749)
(f) administration and corporate costs	(385)	(2,249)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	396	773
1.5 Interest and other costs of finance paid	(37)	(118)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	(277)*	352
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(2,058)	(4,051)

* Grant funding received used for capital acquisitions included in cash flows from investing activities

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(808)	(1,397)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	8	13
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	277*	277
2.6	Net cash from / (used in) investing activities	(523)	(1,107)

* Grant funding received used for capital acquisitions included in cash flows from investing activities

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	1,479
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(58)	(167)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(58)	1,312

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	29,166	30,398
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,058)	(4,051)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(523)	(1,107)

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(58)	1,312
4.5	Effect of movement in exchange rates on cash held	(73)	(98)
4.6	Cash and cash equivalents at end of period	26,454	26,454

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	6,454	6,126
5.2	Call deposits	20,000	23,040
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	26,454	29,166

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	-
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i>		
<i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	N/A	

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(2,058)
8.2 Cash and cash equivalents at quarter end (item 4.6)	26,454
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	26,454
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	13
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 27 April 2026

Authorised by: the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.